News
NEXI
0.0001
NaN%
--
Weekly Report: what happened at NEXI last week (0601-0605)?
Weekly Report · 5d ago
Weekly Report: what happened at NEXI last week (0525-0529)?
Weekly Report · 06/01 10:35
Weekly Report: what happened at NEXI last week (0518-0522)?
Weekly Report · 05/25 10:39
Weekly Report: what happened at NEXI last week (0511-0515)?
Weekly Report · 05/18 10:38
Weekly Report: what happened at NEXI last week (0504-0508)?
Weekly Report · 05/11 10:35
Weekly Report: what happened at NEXI last week (0427-0501)?
Weekly Report · 05/04 10:32
Weekly Report: what happened at NEXI last week (0420-0424)?
Weekly Report · 04/27 10:35
Weekly Report: what happened at NEXI last week (0413-0417)?
Weekly Report · 04/20 10:31
NexImmune (NEXI) was downgraded to a Hold Rating at Citi
TipRanks · 04/14 05:56
Weekly Report: what happened at NEXI last week (0406-0410)?
Weekly Report · 04/13 10:35
Weekly Report: what happened at NEXI last week (0330-0403)?
Weekly Report · 04/06 10:36
Weekly Report: what happened at NEXI last week (0323-0327)?
Weekly Report · 03/30 10:36
Weekly Report: what happened at NEXI last week (0316-0320)?
Weekly Report · 03/23 10:32
Weekly Report: what happened at NEXI last week (0309-0313)?
Weekly Report · 03/16 10:31
Weekly Report: what happened at NEXI last week (0302-0306)?
Weekly Report · 03/09 10:31
Weekly Report: what happened at NEXI last week (0223-0227)?
Weekly Report · 03/02 10:30
Weekly Report: what happened at NEXI last week (0216-0220)?
Weekly Report · 02/23 10:30
Weekly Report: what happened at NEXI last week (0209-0213)?
Weekly Report · 02/16 10:30
Weekly Report: what happened at NEXI last week (0202-0206)?
Weekly Report · 02/09 10:32
Weekly Report: what happened at NEXI last week (0126-0130)?
Weekly Report · 02/02 10:32
More
Webull provides a variety of real-time NEXI stock news. You can receive the latest news about Neximmune, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About NEXI
NexImmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to immunotherapy designed to employ the body’s own T cells to generate an immune response that mimics natural biology. Its product candidates include NEXI-001 in acute myeloid leukemia (AML); NEXI-002 in multiple myeloma (MM), and NEXI-003, a solid tumor product candidate for Human papillomavirus (HPV) related cancers. The Company provides Artificial Immune Modulation (AIM), which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. The Company is also developing new AIM nanoparticle constructs and modalities for clinical evaluation in oncology and autoimmune disorders.